| Dr Leonardo I Valentin, MD | |
|
8 Ave Las Cumbres, Guaynabo, PR 00969 | |
| (787) 740-8787 | |
| Not Available |
| Full Name | Dr Leonardo I Valentin |
|---|---|
| Gender | Male |
| Speciality | Interventional Radiology |
| Experience | 14 Years |
| Location | 8 Ave Las Cumbres, Guaynabo, Puerto Rico |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1962728162 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Professional Hospital Guaynabo Inc | Alt de santa, PR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guaynabo Radiology, Llc | 4082956784 | 3 |
News Archive
A four-year pilot project in Mozambique has reduced the epilepsy treatment gap by more than 30% and is now being rolled out to the entire country.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).
Researchers at the University of North Carolina Chapel Hill and RTI International, a nonprofit research institute, recently found that patients with early rheumatoid arthritis (RA) may see less disease activity and higher remission rates after biologic therapy plus methotrexate (MTX) rather than either treatment alone.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
› Verified 5 days ago
| Entity Name | Centro Medico Del Turabo Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710107883 PECOS PAC ID: 9335051952 Enrollment ID: O20080212000105 |
News Archive
A four-year pilot project in Mozambique has reduced the epilepsy treatment gap by more than 30% and is now being rolled out to the entire country.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).
Researchers at the University of North Carolina Chapel Hill and RTI International, a nonprofit research institute, recently found that patients with early rheumatoid arthritis (RA) may see less disease activity and higher remission rates after biologic therapy plus methotrexate (MTX) rather than either treatment alone.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
› Verified 5 days ago
| Entity Name | Metropolitan Surgical Corp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558350629 PECOS PAC ID: 6204189251 Enrollment ID: O20181022002417 |
News Archive
A four-year pilot project in Mozambique has reduced the epilepsy treatment gap by more than 30% and is now being rolled out to the entire country.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).
Researchers at the University of North Carolina Chapel Hill and RTI International, a nonprofit research institute, recently found that patients with early rheumatoid arthritis (RA) may see less disease activity and higher remission rates after biologic therapy plus methotrexate (MTX) rather than either treatment alone.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
› Verified 5 days ago
| Entity Name | Guaynabo Radiology, Llc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1659858017 PECOS PAC ID: 4082956784 Enrollment ID: O20190429002938 |
News Archive
A four-year pilot project in Mozambique has reduced the epilepsy treatment gap by more than 30% and is now being rolled out to the entire country.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).
Researchers at the University of North Carolina Chapel Hill and RTI International, a nonprofit research institute, recently found that patients with early rheumatoid arthritis (RA) may see less disease activity and higher remission rates after biologic therapy plus methotrexate (MTX) rather than either treatment alone.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
› Verified 5 days ago
| Entity Name | Guaynabo Vascular Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922712413 PECOS PAC ID: 3678922150 Enrollment ID: O20231208002232 |
News Archive
A four-year pilot project in Mozambique has reduced the epilepsy treatment gap by more than 30% and is now being rolled out to the entire country.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).
Researchers at the University of North Carolina Chapel Hill and RTI International, a nonprofit research institute, recently found that patients with early rheumatoid arthritis (RA) may see less disease activity and higher remission rates after biologic therapy plus methotrexate (MTX) rather than either treatment alone.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Leonardo I Valentin, MD Mf15 Plaza 23, Bayamon, PR 00961-4738 Ph: (787) 780-9057 | Dr Leonardo I Valentin, MD 8 Ave Las Cumbres, Guaynabo, PR 00969 Ph: (787) 740-8787 |
News Archive
A four-year pilot project in Mozambique has reduced the epilepsy treatment gap by more than 30% and is now being rolled out to the entire country.
Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced that on August 25, 2009, it received a letter from The NASDAQ Stock Market notifying the Company that, based on its Form 10-Q for the period ended June 30, 2009, NASDAQ has determined that the Company's stockholders' equity does not comply with the minimum $2.5 million stockholders' equity requirement for continued listing on The NASDAQ Capital Market as required by NASDAQ Marketplace Rule 5550(b)(1).
Researchers at the University of North Carolina Chapel Hill and RTI International, a nonprofit research institute, recently found that patients with early rheumatoid arthritis (RA) may see less disease activity and higher remission rates after biologic therapy plus methotrexate (MTX) rather than either treatment alone.
A team of scientists at The Campbell Family Institute for Breast Cancer Research (CFIBCR) at Princess Margaret Hospital and international collaborators have discovered how to trigger an improved immune response to cancer that could be included in new clinical trials that use a patient's own cells to destroy tumours.
› Verified 5 days ago
Alejandra Maria Ramirez-colom, Radiology Medicare: Medicare Enrolled Practice Location: B43 Calle B, Guaynabo, PR 00969 Phone: 787-525-7552 | |
Mrs. Irma Nydia Colon, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 202 Ave Esmeralda, Urb Ponce De Leon, Guaynabo, PR 00969 Phone: 787-272-5656 Fax: 787-720-3232 | |
Dr. Francisco Antonio Viejo Rullan, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 14 Calle Reina De Las Flores, Estancias De Torrimar, Guaynabo, PR 00966 Phone: 787-785-8034 | |
Dr. Marigdalia Ramirez-fort, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 36 Calle Tropical, Guaynabo, PR 00969 Phone: 718-221-5856 | |
Dr. Avery J Knapp Jr., M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 524 Tintillo Hills, Guaynabo, PR 00966 Phone: 646-623-1020 | |
Vivian T. Rivera, MD Radiology Medicare: Medicare Enrolled Practice Location: 280 Ave Marginal Kennedy, Guaynabo, PR 00968 Phone: 973-202-0198 Fax: 787-620-5761 | |
Dr. Ramon A Pizarro Fornaris, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: #5062, Urb Tintillo Hills, Guaynabo, PR 00966 Phone: 787-249-2240 |